Epilepsy
17 cases on antiepileptic drug selection, status epilepticus management, and episodic-disorder pharmacotherapy — choose a case below to open its full multi-voice debate.
A single patient, newly diagnosed with focal epilepsy, choosing a first drug. Both options are genuinely guideline-endorsed — the disagreement is about which real-world constraint should decide it.
A single patient with drug-resistant focal epilepsy starting cenobamate. The efficacy isn't in question — the disagreement is about how to get him through the twelve weeks the label won't let anyone skip.
Two women with genetic generalized epilepsy, both stabilized on valproate, at opposite ends of family planning. The drug and the diagnosis are the same; the risk calculation is not.
A single patient, four years seizure-free, asking to stop his antiepileptic drug. The guideline math on recurrence risk is clear — his own repeat EEG is what complicates it.
A single patient, stable for years, told her insurer will only cover a different generic manufacturer of her antiepileptic drug starting next month. The FDA calls the two products equivalent — the disagreement is about what that guarantees in practice.
A single pediatric patient with confirmed CDKL5 deficiency disorder, already on two antiepileptic drugs. The newest approved agent for her exact diagnosis is available — the disagreement is about how soon to use it.
A single patient with refractory focal epilepsy outside cannabidiol's labeled syndromes. The advocacy pressure to try it is real — so is a documented interaction with the drug he's already taking.
A single patient, still seizing in the emergency department after an initial benzodiazepine dose that was never actually enough. The guideline dose is not in dispute — what to do about the gap already created is.
A single patient in benzodiazepine-refractory status epilepticus. ESETT found levetiracetam, fosphenytoin, and valproate roughly equivalent — his own history is what actually decides between them.
A single patient with occasional nocturnal breakthrough seizures who otherwise feels his epilepsy is well managed. The disagreement is whether SUDEP risk alone justifies pushing his regimen harder.
A single patient whose seizures are actually a missed-dose problem, not a drug-resistance problem. The once-daily drug that could fix it carries a warning that lands close to home.
A single patient on carbamazepine, considering lacosamide as an add-on. Both work on sodium channels, by different enough mechanisms to help — or similar enough to simply add up.
A single patient with new-onset epilepsy who is also on hemodialysis three times a week. Renal clearance is the obvious variable — dialyzability and dosing logistics turn out to matter just as much.
A single patient newly diagnosed with psychogenic nonepileptic seizures after nine years of presumed epilepsy. The diagnosis is settled — how fast to taper the drugs she never needed is not.
A single patient with genetically confirmed episodic ataxia type 2. The standard treatment has real, described effectiveness — it has just never been formally approved for this diagnosis.
A single pediatric patient with Lennox-Gastaut syndrome who has failed five prior antiepileptic drugs. The remaining option that might actually help carries a real risk of aplastic anemia.
A single infant with tuberous-sclerosis-associated infantile spasms. Vigabatrin is the most effective option for exactly this cause — its visual field risk is real, permanent, and unmeasurable in a patient this young.